- ISIN
- US4718711033
- CUSIP
- 471871103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 24, 2021
Highlights
- Market Cap
- $14.38M
- Enterprise Value
- $1.75M
- EPS (TTM)
- -$2.87
- Gross Profit (TTM)
- -$290.00K
- EBITDA (TTM)
- -$72.26M
- Year Range
- $0.42 - $7.19
- Target Price
- $41.67
- ROA (TTM)
- -257.55%
- ROE (TTM)
- -1,604.71%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
JSPR Performance Chart
Jasper Therapeutics, Inc. (JSPR) is down 72.6% since the beginning of the year. At $1 per share, JSPR is trading 93.0% below its 52-week high of $7.
Loading charts...
Returns By Period
Jasper Therapeutics, Inc. (JSPR) has returned -72.60% so far this year and -90.26% over the past 12 months.
Jasper Therapeutics, Inc.
- 1D
- 10.71%
- 1M
- -44.46%
- YTD
- -72.60%
- 6M
- -73.74%
- 1Y
- -90.26%
- 3Y*
- -65.95%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
JSPR Monthly Returns History
Based on dividend-adjusted daily data since Sep 24, 2021, JSPR's average daily return is +0.03%, while the average monthly return is -3.21%.
Historically, 31% of months were positive and 69% were negative. The best month was Jan 2023 with a return of +252.0%, while the worst month was Jan 2025 at -71.7%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 9 months.
On a daily basis, JSPR closed higher 45% of trading days. The best single day was Jan 3, 2023 with a return of +467.4%, while the worst single day was Jan 8, 2025 at -60.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -19.13% | -6.76% | -36.51% | 6.82% | -11.43% | -39.51% | -72.60% | ||||||
| 2025 | -71.66% | -2.15% | -27.49% | 27.67% | 0.18% | 0.91% | -47.75% | -3.45% | -15.00% | -4.20% | -19.30% | -0.54% | -91.44% |
| 2024 | 49.30% | 80.39% | 38.16% | -18.70% | 8.76% | -12.56% | -18.55% | 17.90% | -13.72% | 12.60% | 7.70% | -6.27% | 170.98% |
| 2023 | 252.04% | 13.53% | -6.22% | -26.52% | 16.54% | -11.61% | 10.22% | -18.54% | -43.09% | -5.71% | -6.83% | 28.31% | 63.39% |
| 2022 | -39.75% | -20.72% | -5.33% | -14.08% | 3.93% | -39.12% | -2.07% | 0.53% | -58.47% | -7.49% | -13.97% | -23.11% | -93.85% |
| 2021 | -18.83% | -11.01% | -10.19% | -4.27% | -37.90% |
Benchmark Metrics
Jasper Therapeutics, Inc. has an annualized alpha of -3.79%, beta of 0.82, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 24, 2021.
- This stock participated in 254.32% of S&P 500 Index downside but only -35.58% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -3.79%
- Beta
- 0.82
- R²
- 0.00
- Upside Capture
- -35.58%
- Downside Capture
- 254.32%
Return for Risk
Risk / Return Rank
JSPR ranks 6 for risk / return — in the bottom 6% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Jasper Therapeutics, Inc. (JSPR) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| JSPR | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.88 | ||
| Sortino ratioReturn per unit of downside risk | -4.63 | ||
| Omega ratioGain probability vs. loss probability | 0.73 | 1.37 | -0.64 |
| Calmar ratioReturn relative to maximum drawdown | -0.97 | 2.78 | -3.75 |
| Martin ratioReturn relative to average drawdown | -1.23 | 12.44 | -13.67 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Jasper Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Jasper Therapeutics, Inc. was 99.72%, occurring on Jun 16, 2026. The portfolio has not yet recovered.
The current Jasper Therapeutics, Inc. drawdown is 99.69%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.72%Jun 2026 | 4y 8mo | — | 4y 8moOct 2021 - now |
2021 bear market2021 | -52.31%Oct 2021 | 15d | 3d | 18dSep 2021 - Oct 2021 |
Drawdown Indicators
| JSPR | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.72% | -56.78% | -42.94% |
Max Drawdown (1Y)Largest decline over 1 year | -93.37% | -9.10% | -84.27% |
Max Drawdown (3Y)Largest decline over 3 years | -98.49% | -18.90% | -79.59% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.69% | -1.80% | -97.89% |
Average DrawdownAverage peak-to-trough decline | -88.49% | -10.71% | -77.78% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 73.29% | 2.03% | +71.26% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Jasper Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Jasper Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for JSPR in comparison with other companies in the Biotechnology industry. Currently, JSPR has a P/B value of 4.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with JSPR
Add Jasper Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with JSPR